A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
BCR/ABL1 INHIBITOR RESISTANCE
MessageNeed the patient's fusion type (p210, p190, p205, or p230).
*Collect specimen Monday through Thursday only before 1430 EST. Do not collect the day before a holiday.
*Collect specimen Monday through Thursday only before 1430 EST. Do not collect the day before a holiday.
Test Code
LAB00157
Alias/See Also
LAB00157
Mayo TC: BAKDM
Mayo Test Name: BCR/ABL1, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing
Mayo TC: BAKDM
Mayo Test Name: BCR/ABL1, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing
CPT Codes
81406
Preferred Specimen
10 mL Lavender (EDTA) - Whole Blood
Minimum Volume
8 mL Lavender (EDTA) - Whole Blood
Other Acceptable Specimens
2-4 mL Bone Marrow submitted in an EDTA tube.
Instructions
If BCR/ABL1 fusion type (p190, p205, p210, or p230) is not provided, the qualitative, diagnostic assay for BCR/ABL1 will be performed at an additional charge. If no fusion form (p190, p205, p210, p230) is identified by qualitative testing, this test will be canceled.
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated: 5 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis, moderately to severley clotted
Methodology
Reverse Transcription Polymerase Chain Reaction (RT-PCR) with Sanger Sequencing
Report Available
5-7 days
Clinical Significance
Evaluating patients with chronic myelogenous leukemia and Philadelphia chromosome positive B-cell acute lymphoblastic leukemia receiving tyrosine kinase inhibitor (TKI) therapy, who are apparently failing treatment.
Preferred initial test to identify the presence of acquired BCR/ABL1 mutations associated with TKI-resistance.
Preferred initial test to identify the presence of acquired BCR/ABL1 mutations associated with TKI-resistance.
Performing Laboratory
Mayo Clinic Laboratories